Literature DB >> 15065701

Complications of androgen deprivation therapy: prevention and treatment.

Jeffrey M Holzbeierlein1, Erik Castle, J Brantley Thrasher.   

Abstract

Androgen deprivation, as a form of treatment for prostate cancer, has been used for decades. Within the last decade, however, its use has increased significantly. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment. Some of these side effects (eg, osteoporosis, changes in lipid profiles, and anemia) may be associated with significant morbidity, whereas others (eg, impotence, decreased libido, fatigue, and hot flashes) primarily affect the patient's quality of life. Prevention strategies and treatments exist for many of these side effects. In addition, alternative forms of antiandrogen therapy such as intermittent hormone ablation and antiandrogen monotherapy may be effective, with the added benefit of minimizing side effects. This review focuses on the wide range of side effects associated with androgen ablation as well as preventive and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065701

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  11 in total

1.  Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.

Authors:  Aldo V Bono; Roberta Mazzucchelli; Ilaria Ferrari; Antonio Lopez-Beltran; Andrea B Galosi; Liang Cheng; Rodolfo Montironi
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

2.  Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial.

Authors:  Katherine Regan Sterba; Richard J Swartz; Karen Basen-Engquist; Peter C Black; Curtis A Pettaway
Journal:  Support Care Cancer       Date:  2010-05-25       Impact factor: 3.603

3.  Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).

Authors:  Mei Lu; Svend O Freytag; Hans Stricker; Jae Ho Kim; Kenneth Barton; Benjamin Movsas
Journal:  Contemp Clin Trials       Date:  2011-02-12       Impact factor: 2.226

Review 4.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

Review 5.  Risk factors, pathophysiology, and treatment of hot flashes in cancer.

Authors:  William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter
Journal:  CA Cancer J Clin       Date:  2013-01-25       Impact factor: 508.702

Review 6.  Prostate cancer: psychosocial implications and management.

Authors:  Andrew J Roth; Mark I Weinberger; Christian J Nelson
Journal:  Future Oncol       Date:  2008-08       Impact factor: 3.404

Review 7.  Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy.

Authors:  Mark A Moyad; Robert U Newton; Ulf W Tunn; Damian Gruca
Journal:  Res Rep Urol       Date:  2016-08-16

8.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

9.  Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment: A Population-based Study.

Authors:  Hector J Alonso Quiñones; Bradley J Stish; Clinton Hagen; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimer Dis Assoc Disord       Date:  2020 Apr-Jun       Impact factor: 2.357

10.  Androgen Deprivation Therapy Use and Risk of Mild Cognitive Impairment in Prostate Cancer Patients.

Authors:  Hector Alonso-Quiñones; Bradley J Stish; Jeremiah A Aakre; Clinton E Hagen; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.